m6A Regulator and Potential Drug Response
General Information of the m6A Regulator (ID: REG00006)
| Regulator Name | Methyltransferase-like 14 (METTL14) | ||||
|---|---|---|---|---|---|
| Synonyms |
N6-adenosine-methyltransferase non-catalytic subunit; hMETTL14; KIAA1627
Click to Show/Hide
|
||||
| Gene Name | METTL14 | ||||
| Regulator Type | WRITER ERASER READER | ||||
| Regulator Link | Click to View Full Information of This Regulator | ||||
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Apoptosis regulator Bcl-2 (BCL-2)
MCI-186 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for MCI-186. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MCI-186 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [2] | ||
Venetoclax [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Venetoclax. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Venetoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [3] | ||
ABT-263 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-263. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABT-263 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [4] | ||
Oblimersen [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Oblimersen. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Oblimersen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [5] | ||
RG7601 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for RG7601. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RG7601 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [6] | ||
Thymoquinone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [7] | ||
APG-1252 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-1252. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of APG-1252 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [8] | ||
APG-2575 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-2575. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of APG-2575 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [9] | ||
AZD0466 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AZD0466. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD0466 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [10] | ||
Beclanorsen [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Beclanorsen. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Beclanorsen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [11] | ||
Gossypol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Gossypol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Gossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [12] | ||
Obatoclax [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Obatoclax. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Obatoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [13] | ||
PNT-2258 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for PNT-2258. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PNT-2258 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [14] | ||
AI-850 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AI-850. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AI-850 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [15] | ||
BCL201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BCL201. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BCL201 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [16] | ||
BGB-11417 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BGB-11417. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BGB-11417 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [17] | ||
BP1002 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP1002. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BP1002 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [18] | ||
LP-108 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for LP-108. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LP-108 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [19] | ||
Pc4 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Pc4. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pc4 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [20] | ||
VOB560 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for VOB560. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VOB560 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [21] | ||
2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [22] | ||
4,5-dibenzylbenzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 4,5-dibenzylbenzene-1,2-diol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4,5-dibenzylbenzene-1,2-diol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [23] | ||
5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
Apogossypol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Apogossypol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Apogossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [25] | ||
BP-100-1.02 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP-100-1.02. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BP-100-1.02 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [26] | ||
modified HA14-1 compounds (cancer) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for modified HA14-1 compounds (cancer). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of modified HA14-1 compounds (cancer) through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
QEDIIRNIARHLAQVGDSMDR [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for QEDIIRNIARHLAQVGDSMDR. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of QEDIIRNIARHLAQVGDSMDR through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
TW-37 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for TW-37. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TW-37 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [27] | ||
WL-276 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for WL-276. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of WL-276 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [28] | ||
ABT-737 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-737. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABT-737 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [29] | ||
ATP-citrate synthase (ACLY)
Bempedoic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATP-citrate synthase (ACLY) is a therapeutic target for Bempedoic acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Bempedoic acid through regulating the expression of ATP-citrate synthase (ACLY). | [30], [31] | ||
(-)-hydroxycitrate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATP-citrate synthase (ACLY) is a therapeutic target for (-)-hydroxycitrate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (-)-hydroxycitrate through regulating the expression of ATP-citrate synthase (ACLY). | [30], [32] | ||
SB-201076 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATP-citrate synthase (ACLY) is a therapeutic target for SB-201076. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SB-201076 through regulating the expression of ATP-citrate synthase (ACLY). | [30], [33] | ||
Beta-catenin (CTNNB1)
Recombinant human endostatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). | [34], [35] | ||
C 82 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for C 82. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). | [34], [36] | ||
CEQ-508 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). | [34], [37] | ||
C-X-C chemokine receptor type 4 (CXCR4)
Plerixafor [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Plerixafor. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Plerixafor through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [39] | ||
AMD-070 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for AMD-070. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMD-070 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [40] | ||
Balixafortide [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Balixafortide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Balixafortide through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [4], [38] | ||
BL-8040 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for BL-8040. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BL-8040 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [41] | ||
Ulocuplumab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Ulocuplumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ulocuplumab through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [42] | ||
CTCE-9908 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CTCE-9908. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CTCE-9908 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [15], [38] | ||
POL-6326 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for POL-6326. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of POL-6326 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [43] | ||
TG-0054 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for TG-0054. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TG-0054 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [44] | ||
USL311 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for USL311. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of USL311 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [45] | ||
ALX-0651 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for ALX-0651. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ALX-0651 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [46] | ||
BMS-936564 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for BMS-936564. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS-936564 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [41] | ||
CTCE-0214 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CTCE-0214. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CTCE-0214 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [47] | ||
GMI-1359 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for GMI-1359. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GMI-1359 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [48] | ||
LY2624587 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for LY2624587. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY2624587 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [49] | ||
MSX-122 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for MSX-122. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MSX-122 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [50] | ||
PF-06747143 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for PF-06747143. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-06747143 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [51] | ||
MAb173 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for MAb173. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MAb173 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [52] | ||
AT-009 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for AT-009. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AT-009 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [53] | ||
ATI-2341 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for ATI-2341. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ATI-2341 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [53] | ||
CTCE-0324 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CTCE-0324. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CTCE-0324 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [54] | ||
CX-02 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CX-02. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CX-02 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [53] | ||
CXCL8 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CXCL8. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CXCL8 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [55] | ||
CXCR4 gene disrupted T cells [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CXCR4 gene disrupted T cells. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CXCR4 gene disrupted T cells through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [53] | ||
Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [57] | ||
Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [58] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-). The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
GSK-812397 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for GSK-812397. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK-812397 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [53] | ||
isothiourea-1a [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for isothiourea-1a. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of isothiourea-1a through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [54] | ||
isothiourea-1t [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for isothiourea-1t. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of isothiourea-1t through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [59] | ||
KUR-CXCR4 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for KUR-CXCR4. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KUR-CXCR4 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [53] | ||
LP-0067 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for LP-0067. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LP-0067 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [53] | ||
NB-325 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for NB-325. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NB-325 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [53] | ||
ND-401 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for ND-401. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ND-401 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [53] | ||
T134 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for T134. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of T134 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [59] | ||
T140 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for T140. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of T140 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [59] | ||
T22 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for T22. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of T22 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [60] | ||
TN-14003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for TN-14003. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TN-14003 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [56] | ||
viral macrophage inflammatory protein-II [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for viral macrophage inflammatory protein-II. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of viral macrophage inflammatory protein-II through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [61] | ||
Garnocestim [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Garnocestim. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Garnocestim through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [62] | ||
KRH-2731 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for KRH-2731. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KRH-2731 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [63] | ||
SURADISTA [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for SURADISTA. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SURADISTA through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [38], [64] | ||
C-X-C motif chemokine 10 (CXCL10)
Anti-IP10 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for Anti-IP10. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Anti-IP10 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [37], [65] | ||
BMS-936557 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for BMS-936557. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS-936557 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [65], [66] | ||
JT02 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for JT02. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of JT02 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [65], [67] | ||
MDX-1100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for MDX-1100. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MDX-1100 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [65], [68] | ||
NI-0801 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for NI-0801. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NI-0801 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [65], [69] | ||
NG-641 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for NG-641. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NG-641 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [65], [68] | ||
N-Methylleucine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for N-Methylleucine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-Methylleucine through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [65], [70] | ||
C-X-C motif chemokine 9 (CXCL9)
NG-641 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 9 (CXCL9) is a therapeutic target for NG-641. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NG-641 through regulating the expression of C-X-C motif chemokine 9 (CXCL9). | [65], [71] | ||
C/EBP beta messenger RNA (CEBPB mRNA)
ISIS 116505 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C/EBP beta messenger RNA (CEBPB mRNA) is a therapeutic target for ISIS 116505. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 116505 through regulating the expression of C/EBP beta messenger RNA (CEBPB mRNA). | [72], [73] | ||
ISIS 116507 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C/EBP beta messenger RNA (CEBPB mRNA) is a therapeutic target for ISIS 116507. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 116507 through regulating the expression of C/EBP beta messenger RNA (CEBPB mRNA). | [72], [73] | ||
ISIS 116508 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C/EBP beta messenger RNA (CEBPB mRNA) is a therapeutic target for ISIS 116508. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 116508 through regulating the expression of C/EBP beta messenger RNA (CEBPB mRNA). | [72], [74] | ||
Calmodulin-dependent kinase II (CAMKK2)
STO609 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Calmodulin-dependent kinase II (CAMKK2) is a therapeutic target for STO609. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of STO609 through regulating the expression of Calmodulin-dependent kinase II (CAMKK2). | [75], [76] | ||
Caspase-3 (CASP3)
PAC1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for PAC1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PAC1 through regulating the expression of Caspase-3 (CASP3). | [77], [78] | ||
2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [77], [79] | ||
2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [77], [79] | ||
2-allylisoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-allylisoquinoline-1,3,4-trione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-allylisoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [77], [79] | ||
2-benzylisoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-benzylisoquinoline-1,3,4-trione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-benzylisoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [77], [79] | ||
2-methylisoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-methylisoquinoline-1,3,4-trione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-methylisoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [77], [80] | ||
2-phenethylisoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-phenethylisoquinoline-1,3,4-trione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-phenethylisoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [77], [79] | ||
5-(azepan-1-ylsulfonyl)indoline-2,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 5-(azepan-1-ylsulfonyl)indoline-2,3-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 5-(azepan-1-ylsulfonyl)indoline-2,3-dione through regulating the expression of Caspase-3 (CASP3). | [77], [80] | ||
5-(azetidin-1-ylsulfonyl)indoline-2,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 5-(azetidin-1-ylsulfonyl)indoline-2,3-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 5-(azetidin-1-ylsulfonyl)indoline-2,3-dione through regulating the expression of Caspase-3 (CASP3). | [77], [80] | ||
5-(piperidin-1-ylsulfonyl)indoline-2,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione through regulating the expression of Caspase-3 (CASP3). | [77], [80] | ||
5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione through regulating the expression of Caspase-3 (CASP3). | [77], [81] | ||
Ac-Asp-Glu-Val-Asp-CHO [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for Ac-Asp-Glu-Val-Asp-CHO. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ac-Asp-Glu-Val-Asp-CHO through regulating the expression of Caspase-3 (CASP3). | [77], [79] | ||
Ac-DEVD-CHO [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for Ac-DEVD-CHO. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ac-DEVD-CHO through regulating the expression of Caspase-3 (CASP3). | [77], [82] | ||
AZ10417808 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for AZ10417808. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZ10417808 through regulating the expression of Caspase-3 (CASP3). | [77], [83] | ||
Glionitrin A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for Glionitrin A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Glionitrin A through regulating the expression of Caspase-3 (CASP3). | [77], [84] | ||
Isoquinoline-1,3,4(2H)-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for Isoquinoline-1,3,4(2H)-trione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Isoquinoline-1,3,4(2H)-trione through regulating the expression of Caspase-3 (CASP3). | [77], [79] | ||
M826 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for M826. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of M826 through regulating the expression of Caspase-3 (CASP3). | [77], [85] | ||
PETCM [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for PETCM. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PETCM through regulating the expression of Caspase-3 (CASP3). | [77], [86] | ||
SJ-8002 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for SJ-8002. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SJ-8002 through regulating the expression of Caspase-3 (CASP3). | [77], [87] | ||
CEBPA messenger RNA (CEBPA mRNA)
MTL-CEPBA [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CEBPA messenger RNA (CEBPA mRNA) is a therapeutic target for MTL-CEPBA. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MTL-CEPBA through regulating the expression of CEBPA messenger RNA (CEBPA mRNA). | [72], [88] | ||
Cellular tumor antigen p53 (TP53)
Contusugene ladenovec [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Contusugene ladenovec. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Contusugene ladenovec through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [90] | ||
QPI-1002 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for QPI-1002. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of QPI-1002 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [91] | ||
Thymoquinone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [92] | ||
Ad-p53 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Ad-p53. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ad-p53 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [93] | ||
ALT-801 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ALT-801. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ALT-801 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [94] | ||
APG-115 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for APG-115. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of APG-115 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [95] | ||
APR-246 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for APR-246. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of APR-246 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [96] | ||
Cenersen [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Cenersen. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cenersen through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [97] | ||
INGN-225 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for INGN-225. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of INGN-225 through regulating the expression of Cellular tumor antigen p53 (TP53). | [15], [89] | ||
ISA-P53-01 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ISA-P53-01. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISA-P53-01 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [98] | ||
Kevetrin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Kevetrin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Kevetrin through regulating the expression of Cellular tumor antigen p53 (TP53). | [13], [89] | ||
OPI-1002 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for OPI-1002. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of OPI-1002 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [99] | ||
SGT-53 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for SGT-53. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SGT-53 through regulating the expression of Cellular tumor antigen p53 (TP53). | [15], [89] | ||
CGM097 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for CGM097. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CGM097 through regulating the expression of Cellular tumor antigen p53 (TP53). | [15], [89] | ||
COTI-2 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for COTI-2. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of COTI-2 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [100] | ||
Dendritic cell vaccine [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Dendritic cell vaccine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Dendritic cell vaccine through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [101] | ||
HDM201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for HDM201. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HDM201 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [102] | ||
ONYX-015 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ONYX-015. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ONYX-015 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [103] | ||
SAR-405838 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for SAR-405838. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SAR-405838 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [90] | ||
1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [104] | ||
AHL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for AHL. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AHL through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [105] | ||
NU-8231 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for NU-8231. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NU-8231 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [106] | ||
NUTLIN-3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for NUTLIN-3. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NUTLIN-3 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [107] | ||
INGN-234 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for INGN-234. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of INGN-234 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [108] | ||
Pifithrin-alpha [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Pifithrin-alpha. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pifithrin-alpha through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [109] | ||
TAR-1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for TAR-1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TAR-1 through regulating the expression of Cellular tumor antigen p53 (TP53). | [89], [110] | ||
Cystine/glutamate transporter (SLC7A11)
L-glutamic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cystine/glutamate transporter (SLC7A11) is a therapeutic target for L-glutamic acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of L-glutamic acid through regulating the expression of Cystine/glutamate transporter (SLC7A11). | [34], [111] | ||
SXC-2023 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cystine/glutamate transporter (SLC7A11) is a therapeutic target for SXC-2023. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SXC-2023 through regulating the expression of Cystine/glutamate transporter (SLC7A11). | [34], [112] | ||
Cytochrome P450 1B1 (CYP1B1)
Amodiaquine [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Amodiaquine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Amodiaquine through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [113] | ||
Caffeine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Caffeine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Caffeine through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [114] | ||
Erythromycin stearate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Erythromycin stearate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Erythromycin stearate through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [115] | ||
Estrone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Estrone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Estrone through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [116] | ||
Flutamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Flutamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Flutamide through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [117] | ||
Hydrogen peroxide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Hydrogen peroxide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Hydrogen peroxide through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [118] | ||
Melatonin [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Melatonin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Melatonin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [119] | ||
Oxaliplatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Oxaliplatin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Oxaliplatin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [120] | ||
Procarbazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Procarbazine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Procarbazine through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [121] | ||
Progesterone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Progesterone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Progesterone through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [122] | ||
Rosuvastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Rosuvastatin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Rosuvastatin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [123] | ||
Testosterone cypionate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Testosterone cypionate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Testosterone cypionate through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [122] | ||
Theophylline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Theophylline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Theophylline through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [114] | ||
Estradiol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Estradiol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Estradiol through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [124] | ||
HSDB-3466 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for HSDB-3466. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HSDB-3466 through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [125] | ||
NSC-122758 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for NSC-122758. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NSC-122758 through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [126] | ||
PINOCEMBRIN [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for PINOCEMBRIN. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PINOCEMBRIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [127] | ||
Naringenin [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Naringenin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Naringenin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [129] | ||
3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [129] | ||
4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [129] | ||
ACACETIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for ACACETIN. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ACACETIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
APIGENIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for APIGENIN. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of APIGENIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
Chrysin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Chrysin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Chrysin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
CHRYSOERIOL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for CHRYSOERIOL. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CHRYSOERIOL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
Dibutylphthalate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Dibutylphthalate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Dibutylphthalate through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [130] | ||
DIOSMETIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for DIOSMETIN. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DIOSMETIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
ERIODICTYOL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for ERIODICTYOL. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ERIODICTYOL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
Galangin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Galangin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Galangin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [129] | ||
HOMOERIODICTYOL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for HOMOERIODICTYOL. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HOMOERIODICTYOL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
ISORHAMNETIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for ISORHAMNETIN. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISORHAMNETIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
ISOSAKUTANETIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for ISOSAKUTANETIN. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISOSAKUTANETIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
KAEMPFERIDE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for KAEMPFERIDE. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KAEMPFERIDE through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
KAEMPFEROL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for KAEMPFEROL. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KAEMPFEROL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
TAMARIXETIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for TAMARIXETIN. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TAMARIXETIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [128] | ||
TRISMETHOXYRESVERATROL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for TRISMETHOXYRESVERATROL. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TRISMETHOXYRESVERATROL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [38], [129] | ||
Cytochrome P450 2C8 (CYP2C8)
Almotriptan malate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Almotriptan malate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Almotriptan malate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [132] | ||
Aminophenazone [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Aminophenazone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Aminophenazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [133] | ||
Amiodarone hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Amiodarone hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Amiodarone hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [134] | ||
Amitriptyline hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Amitriptyline hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Amitriptyline hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [135] | ||
Amodiaquine [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Amodiaquine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Amodiaquine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [136] | ||
Anastrozole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Anastrozole. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Anastrozole through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [137] | ||
Apalutamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Apalutamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Apalutamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [138] | ||
Apixaban [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Apixaban. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Apixaban through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [139] | ||
Atorvastatin calcium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Atorvastatin calcium. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Atorvastatin calcium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Azelastine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Azelastine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Azelastine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [141] | ||
Benzyl alcohol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Benzyl alcohol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Benzyl alcohol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [142] | ||
Beraprost [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Beraprost. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Beraprost through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [143] | ||
Brigatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Brigatinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Brigatinib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [144] | ||
Bromfenac [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Bromfenac. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Bromfenac through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [145] | ||
Buprenorphine hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Buprenorphine hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Buprenorphine hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [146] | ||
Cabazitaxel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cabazitaxel. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cabazitaxel through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [147] | ||
Caffeine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Caffeine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Caffeine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [148] | ||
Capsaicin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Capsaicin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Capsaicin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [149] | ||
Carbamazepine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Carbamazepine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Carbamazepine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [150] | ||
Cefaloridine [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cefaloridine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cefaloridine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [151] | ||
Celecoxib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Celecoxib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Celecoxib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [152] | ||
Cerivastatin sodium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cerivastatin sodium. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cerivastatin sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Cisapride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cisapride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cisapride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [153] | ||
Clozapine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Clozapine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Clozapine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [154] | ||
Cyclophosphamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cyclophosphamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyclophosphamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [155] | ||
Dabrafenib mesylate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dabrafenib mesylate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Dabrafenib mesylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Dapsone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dapsone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Dapsone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [156] | ||
Desloratadine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Desloratadine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Desloratadine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [157] | ||
Dexibuprofen [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dexibuprofen. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Dexibuprofen through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [158] | ||
Diazepam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diazepam. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Diazepam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [159] | ||
Diclofenac sodium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diclofenac sodium. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Diclofenac sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [160] | ||
Diethylstilbestrol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diethylstilbestrol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Diethylstilbestrol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [161] | ||
Diltiazem hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diltiazem hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Diltiazem hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [162] | ||
Eltrombopag olamine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Eltrombopag olamine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Eltrombopag olamine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [163] | ||
Enasidenib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Enasidenib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Enasidenib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [164] | ||
Enzalutamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Enzalutamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Enzalutamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Estradiol acetate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol acetate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Estradiol acetate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Estradiol cypionate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol cypionate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Estradiol cypionate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [165] | ||
Estradiol valerate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol valerate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Estradiol valerate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [165] | ||
Eszopiclone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Eszopiclone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Eszopiclone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [166] | ||
Ethinyl estradiol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ethinyl estradiol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ethinyl estradiol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [167] | ||
Fluvastatin sodium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Fluvastatin sodium. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Fluvastatin sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [168] | ||
Glasdegib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Glasdegib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Glasdegib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [169] | ||
Halofantrine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Halofantrine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Halofantrine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [170] | ||
Ibuprofen [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ibuprofen. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ibuprofen through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [158] | ||
Ifosfamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ifosfamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ifosfamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [155] | ||
Imatinib mesylate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Imatinib mesylate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Imatinib mesylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Irbesartan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Irbesartan. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Irbesartan through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [167] | ||
Istradefylline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Istradefylline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Istradefylline through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [171] | ||
Ixazomib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ixazomib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ixazomib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [172] | ||
Ketobemidone [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ketobemidone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ketobemidone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [173] | ||
Ketorolac [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ketorolac. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ketorolac through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [174] | ||
Lansoprazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lansoprazole. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Lansoprazole through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [175] | ||
Lapatinib ditosylate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lapatinib ditosylate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Lapatinib ditosylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [176] | ||
Levomilnacipran [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Levomilnacipran. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Levomilnacipran through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [177] | ||
Lidocaine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lidocaine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Lidocaine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [178] | ||
Loperamide hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Loperamide hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Loperamide hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [179] | ||
Loratadine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Loratadine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Loratadine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Lorlatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lorlatinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Lorlatinib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [180] | ||
Losartan potassium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Losartan potassium. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Losartan potassium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [181] | ||
Lovastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lovastatin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Lovastatin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [182] | ||
Mefenamic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mefenamic acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Mefenamic acid through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Meloxicam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Meloxicam. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Meloxicam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [183] | ||
Mephenytoin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mephenytoin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Mephenytoin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [184] | ||
Mestranol [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mestranol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Mestranol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [185] | ||
Methadone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Methadone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Methadone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [186] | ||
Mirtazapine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mirtazapine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Mirtazapine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [178] | ||
Montelukast sodium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Montelukast sodium. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Montelukast sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [187] | ||
Morphine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Morphine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Morphine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [188] | ||
Mycophenolate mofetil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mycophenolate mofetil. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Mycophenolate mofetil through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [189] | ||
Naloxone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Naloxone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Naloxone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [146] | ||
Naproxen [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Naproxen. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Naproxen through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [190] | ||
Nicardipine hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Nicardipine hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Nicardipine hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [178] | ||
Nicotine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Nicotine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Nicotine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [191] | ||
Nilotinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Nilotinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Nilotinib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Ombitasvir [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ombitasvir. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ombitasvir through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [192] | ||
Omeprazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Omeprazole. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Omeprazole through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [193] | ||
Pazopanib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pazopanib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pazopanib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [194] | ||
Pentamidine isethionate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pentamidine isethionate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pentamidine isethionate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [195] | ||
Perphenazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Perphenazine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Perphenazine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [196] | ||
Phenobarbital [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Phenobarbital. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Phenobarbital through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [197] | ||
Phenprocoumon [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Phenprocoumon. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Phenprocoumon through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [198] | ||
Phenytoin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Phenytoin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Phenytoin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [178] | ||
Pioglitazone hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pioglitazone hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pioglitazone hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [199] | ||
Piroxicam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Piroxicam. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Piroxicam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [200] | ||
Pitavastatin calcium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pitavastatin calcium. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pitavastatin calcium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [201] | ||
Propofol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Propofol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Propofol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [202] | ||
Quinidine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Quinidine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Quinidine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Quinine sulfate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Quinine sulfate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Quinine sulfate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Repaglinide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Repaglinide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Repaglinide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [203] | ||
Riociguat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Riociguat. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Riociguat through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [204] | ||
Rofecoxib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Rofecoxib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Rofecoxib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Rosiglitazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Rosiglitazone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Rosiglitazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [205] | ||
Selegiline hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Selegiline hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Selegiline hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [206] | ||
Selexipag [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Selexipag. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Selexipag through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [207] | ||
Simvastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Simvastatin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Simvastatin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [208] | ||
Sitagliptin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sitagliptin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sitagliptin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [209] | ||
Sulfadiazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sulfadiazine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sulfadiazine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [210] | ||
Sulfamethoxazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sulfamethoxazole. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sulfamethoxazole through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [211] | ||
Sulfinpyrazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sulfinpyrazone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sulfinpyrazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [178] | ||
Tazarotene [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Tazarotene. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Tazarotene through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [212] | ||
Tegafur [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Tegafur. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Tegafur through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [213] | ||
Temazepam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Temazepam. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Temazepam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [214] | ||
Terbinafine hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Terbinafine hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Terbinafine hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [166] | ||
Testosterone cypionate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Testosterone cypionate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Testosterone cypionate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Testosterone enanthate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Testosterone enanthate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Testosterone enanthate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Testosterone undecanoate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Testosterone undecanoate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Testosterone undecanoate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
Thalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Thalidomide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thalidomide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [215] | ||
Tolbutamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Tolbutamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Tolbutamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [216] | ||
Torasemide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Torasemide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Torasemide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [217] | ||
Treprostinil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Treprostinil. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Treprostinil through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [218] | ||
Trifarotene [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trifarotene. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Trifarotene through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [219] | ||
Trimethadione [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trimethadione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Trimethadione through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [220] | ||
Trimethoprim [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trimethoprim. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Trimethoprim through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [221] | ||
Troglitazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Troglitazone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Troglitazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [222] | ||
Velpatasvir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Velpatasvir. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Velpatasvir through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [223] | ||
Verapamil hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Verapamil hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Verapamil hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [224] | ||
Vortioxetine hydrobromide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Vortioxetine hydrobromide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Vortioxetine hydrobromide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [225] | ||
Voxilaprevir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Voxilaprevir. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Voxilaprevir through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [223] | ||
Warfarin sodium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Warfarin sodium. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Warfarin sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [190] | ||
Zafirlukast [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Zafirlukast. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Zafirlukast through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [221] | ||
Zidovudine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Zidovudine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Zidovudine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [178] | ||
Zopiclone [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Zopiclone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Zopiclone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [226] | ||
BMS-298585 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for BMS-298585. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS-298585 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [227] | ||
BNP-1350 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for BNP-1350. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BNP-1350 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [228] | ||
CKD-501 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for CKD-501. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CKD-501 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [229] | ||
CYT-387 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for CYT-387. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CYT-387 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [230] | ||
Dasabuvir [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dasabuvir. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Dasabuvir through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [231] | ||
Domperidone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Domperidone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Domperidone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [232] | ||
DRF-2593 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for DRF-2593. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DRF-2593 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [229] | ||
EMD-128130 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for EMD-128130. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EMD-128130 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [233] | ||
Estradiol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Estradiol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [140] | ||
LAS-17177 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LAS-17177. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LAS-17177 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [234] | ||
LAU-7b [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LAU-7b. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LAU-7b through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [235] | ||
LY-2484595 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LY-2484595. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY-2484595 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [236] | ||
NSC-122758 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for NSC-122758. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NSC-122758 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [237] | ||
QLT-091001 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for QLT-091001. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of QLT-091001 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [237] | ||
Rivoglitazone [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Rivoglitazone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Rivoglitazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [238] | ||
AZD-2014 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for AZD-2014. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD-2014 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [239] | ||
GSK-1278863 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for GSK-1278863. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK-1278863 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [240] | ||
TAK-652 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for TAK-652. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TAK-652 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [241] | ||
AG-1549 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for AG-1549. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AG-1549 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [242] | ||
AZD-9496 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for AZD-9496. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD-9496 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [243] | ||
H3B-6545 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for H3B-6545. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of H3B-6545 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [244] | ||
M-813 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for M-813. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of M-813 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [245] | ||
MK-0822 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for MK-0822. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MK-0822 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [246] | ||
Antipyrine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Antipyrine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Antipyrine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [166] | ||
Cyamemazine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cyamemazine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cyamemazine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [247] | ||
Paraoxon [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Paraoxon. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Paraoxon through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [248] | ||
ABT-001 [Discontinued]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for ABT-001. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABT-001 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [249] | ||
ADD-3878 [Discontinued]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for ADD-3878. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ADD-3878 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [229] | ||
Aleglitazar [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Aleglitazar. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Aleglitazar through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [250] | ||
ML-3000 [Discontinued]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for ML-3000. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ML-3000 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [131], [166] | ||
DNA-binding factor KBF1 (p105)
CAT 1004 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA-binding factor KBF1 (p105) is a therapeutic target for CAT 1004. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CAT 1004 through regulating the expression of DNA-binding factor KBF1 (p105). | [251], [252] | ||
P54 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA-binding factor KBF1 (p105) is a therapeutic target for P54. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of P54 through regulating the expression of DNA-binding factor KBF1 (p105). | [251], [253] | ||
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
KH-CB19 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for KH-CB19. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KH-CB19 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). | [254], [255] | ||
leucettine L41 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for leucettine L41. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of leucettine L41 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). | [254], [256] | ||
ML315 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for ML315. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ML315 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). | [254], [257] | ||
WO2013026806C72 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for WO2013026806C72 . The Methyltransferase-like 14 (METTL14) has potential in affecting the response of WO2013026806C72 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). | [254], [256] | ||
Ephrin type-A receptor 3 (EPHA3)
Ifabotuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 3 (EPHA3) is a therapeutic target for Ifabotuzumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ifabotuzumab through regulating the expression of Ephrin type-A receptor 3 (EPHA3). | [258], [259] | ||
KB-004 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 3 (EPHA3) is a therapeutic target for KB-004. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KB-004 through regulating the expression of Ephrin type-A receptor 3 (EPHA3). | [258], [260] | ||
Ephrin type-B receptor 2 (EPHB2)
BVD-523 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [261], [262] | ||
SEphB4-HSA [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for SEphB4-HSA. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SEphB4-HSA through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [261], [263] | ||
KO-947 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for KO-947. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KO-947 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [15], [261] | ||
MK-8353 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for MK-8353. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MK-8353 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [15], [261] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [261], [264] | ||
SNEWIQPRLPQH [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for SNEWIQPRLPQH. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SNEWIQPRLPQH through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [15], [261] | ||
Epidermal growth factor receptor (EGFR)
Afatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Afatinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Afatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [266] | ||
Cetuximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cetuximab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cetuximab through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [267] | ||
Dacomitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Dacomitinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Dacomitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [268] | ||
Epidermal growth factor [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epidermal growth factor. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Epidermal growth factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [269] | ||
HEGF [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HEGF. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [270] | ||
Icotinib hydrochloride [Registered]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Icotinib hydrochloride. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Icotinib hydrochloride through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [271] | ||
Lapatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Lapatinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Lapatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [272] | ||
Merimepodib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Merimepodib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Merimepodib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [273] | ||
Necitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Necitumumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Necitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [274] | ||
NERATINIB MALEATE [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NERATINIB MALEATE. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NERATINIB MALEATE through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [275] | ||
Nitroglycerin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Nitroglycerin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Nitroglycerin through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [273] | ||
Panitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Panitumumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Panitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [276] | ||
SKI-758 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SKI-758. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SKI-758 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
Vandetanib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Vandetanib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Vandetanib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [278] | ||
AC0010 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AC0010. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AC0010 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [279] | ||
Almonertinib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Almonertinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Almonertinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [280] | ||
Amivantamab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Amivantamab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Amivantamab through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [281] | ||
ASP1929 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP1929. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ASP1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [282] | ||
CO-1686 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CO-1686. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CO-1686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
DE-766 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for DE-766. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DE-766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [283] | ||
EGF816 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGF816. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EGF816 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
HKI-272 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-272. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HKI-272 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [284] | ||
Indium-111 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Indium-111. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Indium-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [90], [265] | ||
Rindopepimut [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Rindopepimut. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Rindopepimut through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [285] | ||
SYM-004 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-004. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SYM-004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [286] | ||
Varlitinib [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Varlitinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Varlitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [7], [265] | ||
Zalutumumab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Zalutumumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Zalutumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [268] | ||
ABT-414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABT-414. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABT-414 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [267] | ||
ABX-EGF [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABX-EGF. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABX-EGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [287] | ||
AFM24 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM24. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AFM24 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [288] | ||
ASP8273 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP8273. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ASP8273 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [289] | ||
BDTX-189 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BDTX-189. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BDTX-189 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [290] | ||
BMS-599626 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-599626. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS-599626 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [266] | ||
BMS-690514 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-690514. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS-690514 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [285] | ||
CART-EGFR [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CART-EGFR. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CART-EGFR through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [291] | ||
CetuGEX [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CetuGEX. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CetuGEX through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [292] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CI-1033. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CI-1033 through regulating the expression of Epidermal growth factor receptor (EGFR). | [15], [265] | ||
CK-101 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CK-101. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CK-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [15], [265] | ||
Depatuxizumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Depatuxizumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Depatuxizumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [15], [265] | ||
EGFR antisense DNA [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR antisense DNA. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EGFR antisense DNA through regulating the expression of Epidermal growth factor receptor (EGFR). | [15], [265] | ||
EGFR CART [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR CART. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EGFR CART through regulating the expression of Epidermal growth factor receptor (EGFR). | [41], [265] | ||
EMB-01 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMB-01. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EMB-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [293] | ||
EMD 55900 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMD 55900. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EMD 55900 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [294] | ||
HER1-VSSP vaccine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HER1-VSSP vaccine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HER1-VSSP vaccine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [295] | ||
HM-78136B [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-78136B. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HM-78136B through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [296] | ||
Matuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Matuzumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Matuzumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [297] | ||
MEHD-7945A [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MEHD-7945A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MEHD-7945A through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [298] | ||
Pelitinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pelitinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pelitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [299] | ||
RM-1929 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-1929. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RM-1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [300] | ||
SN-32793 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SN-32793. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SN-32793 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [301] | ||
Sym013 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym013. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sym013 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [302] | ||
Sym015 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym015. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sym015 through regulating the expression of Epidermal growth factor receptor (EGFR). | [41], [265] | ||
Tarloxotinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Tarloxotinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Tarloxotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [303] | ||
TT-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TT-100. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TT-100 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [304] | ||
VATALANIB [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for VATALANIB. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VATALANIB through regulating the expression of Epidermal growth factor receptor (EGFR). | [90], [265] | ||
ZN-e4 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ZN-e4. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ZN-e4 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [305] | ||
AMG 595 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AMG 595. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMG 595 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [306] | ||
Anti-EGFR CAR T [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR CAR T. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Anti-EGFR CAR T through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [307] | ||
AP32788 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AP32788. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AP32788 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [308] | ||
AST-1306 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AST-1306. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AST-1306 through regulating the expression of Epidermal growth factor receptor (EGFR). | [90], [265] | ||
BCA101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BCA101. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BCA101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [309] | ||
BIBX-1382 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BIBX-1382. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BIBX-1382 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [310] | ||
Cipatinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cipatinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cipatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [311] | ||
CLN-081 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CLN-081. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CLN-081 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [312] | ||
CUDC-101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CUDC-101. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CUDC-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [313] | ||
D2C7 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for D2C7. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of D2C7 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [314] | ||
EGFR806-specific CAR T cell [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR806-specific CAR T cell. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EGFR806-specific CAR T cell through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [315] | ||
IMGN289 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IMGN289. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of IMGN289 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
JNJ-26483327 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for JNJ-26483327. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of JNJ-26483327 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [316] | ||
LY3164530 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LY3164530. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY3164530 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [317] | ||
MCLA-158 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MCLA-158. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MCLA-158 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [318] | ||
MM-151 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MM-151. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MM-151 through regulating the expression of Epidermal growth factor receptor (EGFR). | [15], [265] | ||
MR1-1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MR1-1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MR1-1 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [319] | ||
PF-05230907 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF-05230907. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-05230907 through regulating the expression of Epidermal growth factor receptor (EGFR). | [41], [265] | ||
Pyrotinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pyrotinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pyrotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [320] | ||
S-222611 [Phase 1b]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for S-222611. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of S-222611 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
SI-B001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SI-B001. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SI-B001 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [321] | ||
SYN004 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYN004. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SYN004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [41], [265] | ||
111In-hEGF [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 111In-hEGF. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 111In-hEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [322] | ||
(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [323] | ||
(3-Bromo-phenyl)-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-quinazolin-4-yl-amine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (3-Bromo-phenyl)-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [324] | ||
(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [325] | ||
(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [323] | ||
10-hydroxy-18-methoxybetaenone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 10-hydroxy-18-methoxybetaenone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 10-hydroxy-18-methoxybetaenone through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [323] | ||
2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [326] | ||
2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [327] | ||
2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [323] | ||
2-cyano-3-(3,4-dihydroxyphenyl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [323] | ||
2-methoxy-4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-methoxy-4-(2-nitrovinyl)phenol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-methoxy-4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [323] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [328] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [329] | ||
3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [330] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [331] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [332] | ||
3-Pyridin-4-yl-quinoline-6,7-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-Pyridin-4-yl-quinoline-6,7-diol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-Pyridin-4-yl-quinoline-6,7-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [333] | ||
4-(2-nitroprop-1-enyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitroprop-1-enyl)benzene-1,2-diol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(2-nitroprop-1-enyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [323] | ||
4-(2-nitrovinyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)benzene-1,2-diol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(2-nitrovinyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [334] | ||
4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)phenol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [323] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [335] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [324] | ||
4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [323] | ||
4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [336] | ||
4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [337] | ||
4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [338] | ||
4557W [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4557W. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4557W through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [339] | ||
5,6-Bis-p-tolylamino-isoindole-1,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5,6-Bis-p-tolylamino-isoindole-1,3-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 5,6-Bis-p-tolylamino-isoindole-1,3-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [340] | ||
5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [341] | ||
6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [338] | ||
6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [338] | ||
6,7-diethoxy-4-styrylquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-styrylquinazoline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6,7-diethoxy-4-styrylquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [338] | ||
6,7-dimethoxy-4-(2-phenylethynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [338] | ||
6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [338] | ||
6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [342] | ||
6,7-dimethoxy-N-m-tolylquinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-N-m-tolylquinazolin-4-amine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6,7-dimethoxy-N-m-tolylquinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [331] | ||
6-chloro-N-(3-chlorophenyl)quinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [331] | ||
AFM-21 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM-21. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AFM-21 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
AG 112 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 112. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AG 112 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [343] | ||
AG 9 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 9. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AG 9 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
AG-213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-213. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AG-213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [323] | ||
AG-538 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-538. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AG-538 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [344] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG1478. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AG1478 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [345] | ||
AGT-2000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AGT-2000. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AGT-2000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
AL-6802 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AL-6802. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AL-6802 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
Anti-EGFR humanized mabs [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR humanized mabs. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Anti-EGFR humanized mabs through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
Anti-EGFR mab [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR mab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Anti-EGFR mab through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
ARX-AHD [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ARX-AHD. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ARX-AHD through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [335] | ||
Benzyl-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzyl-quinazolin-4-yl-amine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Benzyl-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [336] | ||
Bmab-200 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Bmab-200. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Bmab-200 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
BPIQ-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BPIQ-I. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BPIQ-I through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [346] | ||
CL-387785 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CL-387785. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CL-387785 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [337] | ||
Cochliobolic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cochliobolic acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cochliobolic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [347] | ||
EDP-13 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EDP-13. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EDP-13 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
EGFR inhibitor [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR inhibitor. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EGFR inhibitor through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [348] | ||
Epitinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epitinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Epitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
FHT-2107 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for FHT-2107. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of FHT-2107 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
GI-3000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for GI-3000. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GI-3000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
HDS-029 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HDS-029. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HDS-029 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [349] | ||
HKI-9924129 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-9924129. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HKI-9924129 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [350] | ||
HM-61713B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-61713B. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HM-61713B through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
HTS-00213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-00213. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HTS-00213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [331] | ||
HTS-02876 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-02876. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HTS-02876 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [351] | ||
HTS-05058 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-05058. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HTS-05058 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [328] | ||
ICR 62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ICR 62. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ICR 62 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [352] | ||
IPS-01003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IPS-01003. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of IPS-01003 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
LA22-radioimmunoconjugates [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LA22-radioimmunoconjugates. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LA22-radioimmunoconjugates through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
LAVENDUSTIN A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LAVENDUSTIN A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LAVENDUSTIN A through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [338] | ||
mabionHER2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for mabionHER2. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of mabionHER2 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
MDP-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MDP-01. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MDP-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
MG-111 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MG-111. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MG-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [353] | ||
MT-062 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MT-062. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MT-062 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [354] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [355] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [356] | ||
N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [344] | ||
N-(4-(phenylamino)quinazolin-6-yl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-(phenylamino)quinazolin-6-yl)acrylamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(4-(phenylamino)quinazolin-6-yl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [352] | ||
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [326] | ||
N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [324] | ||
N4-(3-chlorophenyl)quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-chlorophenyl)quinazoline-4,6-diamine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N4-(3-chlorophenyl)quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [354] | ||
N4-(3-methylphenyl)-4,6-quinazolinediamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-methylphenyl)-4,6-quinazolinediamine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N4-(3-methylphenyl)-4,6-quinazolinediamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [328] | ||
NRC-2694 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NRC-2694. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NRC-2694 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
ON-128 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ON-128. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ON-128 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [324] | ||
OSI-75 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for OSI-75. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of OSI-75 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [357] | ||
PD-0166326 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0166326. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PD-0166326 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [325] | ||
PD-0173956 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0173956. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PD-0173956 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [325] | ||
PD-158780 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-158780. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PD-158780 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [324] | ||
PD-168393 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-168393. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PD-168393 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [356] | ||
PD182905 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD182905. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PD182905 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [301] | ||
PF 5208766 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF 5208766. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF 5208766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [358] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PP121. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PP121 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [359] | ||
RG-50810 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG-50810. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RG-50810 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [351] | ||
RM-6427 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-6427. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RM-6427 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [328] | ||
RX-1792 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RX-1792. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RX-1792 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
SYM-011 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-011. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SYM-011 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
TGF alpha [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TGF alpha. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TGF alpha through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
Theliatinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Theliatinib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Theliatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [360] | ||
WHI-P154 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WHI-P154. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of WHI-P154 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [342] | ||
WZ-3146 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WZ-3146. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of WZ-3146 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [277] | ||
AZD-9935 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD-9935. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD-9935 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [361] | ||
AZD4769 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD4769. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD4769 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [266] | ||
CGP-52411 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-52411. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CGP-52411 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [362] | ||
CGP-53353 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-53353. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CGP-53353 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [301] | ||
Heparin-EGF-like factor [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Heparin-EGF-like factor. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Heparin-EGF-like factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [363] | ||
PD-153035 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-153035. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PD-153035 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [364] | ||
PKI166 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PKI166. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PKI166 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [365] | ||
RG7160 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG7160. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RG7160 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [366] | ||
TAK165 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TAK165. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TAK165 through regulating the expression of Epidermal growth factor receptor (EGFR). | [265], [367] | ||
Fascin (FSCN1)
NP-G2-044 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fascin (FSCN1) is a therapeutic target for NP-G2-044. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NP-G2-044 through regulating the expression of Fascin (FSCN1). | [368], [369] | ||
Fibroblast growth factor receptor 4 (FGFR4)
FGF401 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for FGF401. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of FGF401 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). | [15], [34] | ||
INCB62079 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for INCB62079. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of INCB62079 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). | [34], [370] | ||
ISIS-FGFR4 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for ISIS-FGFR4. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS-FGFR4 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). | [34], [332] | ||
BLU-554 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for BLU-554. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BLU-554 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). | [15], [34] | ||
H3B-6527 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for H3B-6527. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of H3B-6527 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). | [15], [34] | ||
ABC-4 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for ABC-4. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABC-4 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). | [34], [371] | ||
ACTB-1003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for ACTB-1003. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ACTB-1003 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). | [15], [34] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for Ro-4396686. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ro-4396686 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). | [34], [372] | ||
PD-0183812 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for PD-0183812. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PD-0183812 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). | [15], [34] | ||
Forkhead box protein O1A (FOXO1)
AS-1708727 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for AS-1708727. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AS-1708727 through regulating the expression of Forkhead box protein O1A (FOXO1). | [373], [374] | ||
ISIS 188755 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188755. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 188755 through regulating the expression of Forkhead box protein O1A (FOXO1). | [373], [375] | ||
ISIS 188757 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188757. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 188757 through regulating the expression of Forkhead box protein O1A (FOXO1). | [373], [375] | ||
ISIS 188759 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188759. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 188759 through regulating the expression of Forkhead box protein O1A (FOXO1). | [373], [375] | ||
ISIS 188761 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188761. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 188761 through regulating the expression of Forkhead box protein O1A (FOXO1). | [373], [375] | ||
ISIS 188763 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188763. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 188763 through regulating the expression of Forkhead box protein O1A (FOXO1). | [373], [375] | ||
ISIS 188778 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188778. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 188778 through regulating the expression of Forkhead box protein O1A (FOXO1). | [373], [375] | ||
ISIS 188780 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188780. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 188780 through regulating the expression of Forkhead box protein O1A (FOXO1). | [373], [375] | ||
ISIS 188781 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188781. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 188781 through regulating the expression of Forkhead box protein O1A (FOXO1). | [373], [375] | ||
ISIS 188782 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188782. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 188782 through regulating the expression of Forkhead box protein O1A (FOXO1). | [373], [376] | ||
Glycogen synthase kinase-3 beta (GSK-3B)
AMO-02 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for AMO-02. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMO-02 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [377] | ||
9-ING-41 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 9-ING-41. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 9-ING-41 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [378] | ||
Lithium [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for Lithium. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Lithium through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [379] | ||
LY2090314 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for LY2090314. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY2090314 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [380] | ||
Neu-120 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for Neu-120. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Neu-120 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [381] | ||
Tideglusib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for Tideglusib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Tideglusib through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [382] | ||
(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for (E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [383] | ||
12,13-DEHYDRO-8-O-ACETYLMANZAMINE A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 12,13-DEHYDRO-8-O-ACETYLMANZAMINE A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 12,13-DEHYDRO-8-O-ACETYLMANZAMINE A through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [384] | ||
12,13-DEHYDROMANZAMINE A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 12,13-DEHYDROMANZAMINE A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 12,13-DEHYDROMANZAMINE A through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [384] | ||
3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [385] | ||
3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [386] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [387] | ||
4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [369] | ||
6-deoxymanzamine X [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 6-deoxymanzamine X. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6-deoxymanzamine X through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [384] | ||
8-O-(4-bromobenzenesulfonyl)manzamine F [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 8-O-(4-bromobenzenesulfonyl)manzamine F. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 8-O-(4-bromobenzenesulfonyl)manzamine F through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [384] | ||
8-O-(4-chlorobenzenesulfonyl)manzamine F [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 8-O-(4-chlorobenzenesulfonyl)manzamine F. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 8-O-(4-chlorobenzenesulfonyl)manzamine F through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [388] | ||
8-O-(4-toluenesulfonyl)manzamine A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 8-O-(4-toluenesulfonyl)manzamine A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 8-O-(4-toluenesulfonyl)manzamine A through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [388] | ||
8-OH-MANZAMINE A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 8-OH-MANZAMINE A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 8-OH-MANZAMINE A through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [389] | ||
9-N-ETHYL-8-ETHOXY-MANZAMINE A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 9-N-ETHYL-8-ETHOXY-MANZAMINE A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 9-N-ETHYL-8-ETHOXY-MANZAMINE A through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [384] | ||
9-N-METHYL-8-METHOXY-MANZAMINE A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for 9-N-METHYL-8-METHOXY-MANZAMINE A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 9-N-METHYL-8-METHOXY-MANZAMINE A through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [384] | ||
alsterpaullone 2-cyanoethyl [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for alsterpaullone 2-cyanoethyl. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of alsterpaullone 2-cyanoethyl through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [390] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for AMP-PNP. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMP-PNP through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [391] | ||
AS-601245 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for AS-601245. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AS-601245 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [392] | ||
AZAKENPAULLONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for AZAKENPAULLONE. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZAKENPAULLONE through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [393] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for Bisindolylmaleimide-I. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [393] | ||
BX-795 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for BX-795. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BX-795 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [390] | ||
BX-912 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for BX-912. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BX-912 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [342] | ||
CHIR-98014 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for CHIR-98014. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CHIR-98014 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [394] | ||
CHIR-98023 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for CHIR-98023. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CHIR-98023 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for CI-1040. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CI-1040 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [396] | ||
CP-70949 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for CP-70949. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CP-70949 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [397] | ||
CT-98024 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for CT-98024. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CT-98024 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [398] | ||
DM-204 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for DM-204. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DM-204 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [378] | ||
ELLAGIC ACID [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for ELLAGIC ACID. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [385] | ||
GSK-3beta inhibitor II [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for GSK-3beta inhibitor II. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK-3beta inhibitor II through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [399] | ||
GSK-3beta inhibitor XI [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for GSK-3beta inhibitor XI. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK-3beta inhibitor XI through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [400] | ||
I-5 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for I-5. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of I-5 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [96] | ||
IM-12 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for IM-12. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of IM-12 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [401] | ||
indirubin deriv. 8a [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for indirubin deriv. 8a. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of indirubin deriv. 8a through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [402] | ||
K00244 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for K00244. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of K00244 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [403] | ||
L-779450 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for L-779450. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of L-779450 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [404] | ||
LEUCETTAMINE B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for LEUCETTAMINE B. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LEUCETTAMINE B through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [405] | ||
MANZAMINE A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for MANZAMINE A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MANZAMINE A through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [384] | ||
Manzamine E [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for Manzamine E. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Manzamine E through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [384] | ||
Manzamine Y [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for Manzamine Y. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Manzamine Y through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [388] | ||
N,8-diphenyl-9H-purin-6-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N,8-diphenyl-9H-purin-6-amine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N,8-diphenyl-9H-purin-6-amine through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [388] | ||
N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [406] | ||
N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [405] | ||
N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [383] | ||
N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-benzyl-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-benzyl-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-benzyl-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-bromo-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-bromo-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-bromo-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-chloro-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-chloro-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-chloro-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(6-phenethyl-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-phenethyl-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-phenethyl-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [383] | ||
N-(6-phenyl-1H-indazol-3-yl)butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(6-phenyl-1H-indazol-3-yl)butyramide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(6-phenyl-1H-indazol-3-yl)butyramide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [385] | ||
Neo-kauluamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for Neo-kauluamine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Neo-kauluamine through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [407] | ||
NU-6102 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for NU-6102. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NU-6102 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [408] | ||
PAULLONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for PAULLONE. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PAULLONE through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [377] | ||
PF-228 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for PF-228. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-228 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [395] | ||
PYRAZOLOPYRIDAZINE 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for PYRAZOLOPYRIDAZINE 1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PYRAZOLOPYRIDAZINE 1 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [391] | ||
PYRAZOLOPYRIDAZINE 2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [405] | ||
Quinoxaline1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for Quinoxaline1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Quinoxaline1 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [409] | ||
RGB-286147 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for RGB-286147. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RGB-286147 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [342] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for Ro31-8220. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ro31-8220 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [410] | ||
SB-415286 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for SB-415286. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SB-415286 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [369] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for STAUROSPORINONE. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of STAUROSPORINONE through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [411] | ||
Thieno analogue of kenpaullone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for Thieno analogue of kenpaullone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thieno analogue of kenpaullone through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [412] | ||
TWS-119 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for TWS-119. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TWS-119 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [413] | ||
AZD-1080 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for AZD-1080. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD-1080 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [414] | ||
RO-320432 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for RO-320432. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RO-320432 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [415] | ||
SAN-61 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for SAN-61. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SAN-61 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [34], [416] | ||
Insulin-like growth factor-I (IGF1)
Xentuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-I (IGF1) is a therapeutic target for Xentuzumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Xentuzumab through regulating the expression of Insulin-like growth factor-I (IGF1). | [417], [418] | ||
BI-836845 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-I (IGF1) is a therapeutic target for BI-836845. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BI-836845 through regulating the expression of Insulin-like growth factor-I (IGF1). | [41], [417] | ||
MEDI-573 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-I (IGF1) is a therapeutic target for MEDI-573. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MEDI-573 through regulating the expression of Insulin-like growth factor-I (IGF1). | [417], [419] | ||
Interferon-beta (IFNB1)
Interferon beta-1a [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Interferon beta-1a. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Interferon beta-1a through regulating the expression of Interferon-beta (IFNB1). | [420], [421] | ||
PEGylated IFN beta 1-a [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for PEGylated IFN beta 1-a. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PEGylated IFN beta 1-a through regulating the expression of Interferon-beta (IFNB1). | [420], [422] | ||
PLEGRIDY [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for PLEGRIDY. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PLEGRIDY through regulating the expression of Interferon-beta (IFNB1). | [420], [423] | ||
Biferonex [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Biferonex. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Biferonex through regulating the expression of Interferon-beta (IFNB1). | [420], [424] | ||
FP-1201 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for FP-1201. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of FP-1201 through regulating the expression of Interferon-beta (IFNB1). | [420], [425] | ||
NU-100 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for NU-100. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NU-100 through regulating the expression of Interferon-beta (IFNB1). | [420], [426] | ||
AZ-01, PEGylated interferon-beta [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for AZ-01, PEGylated interferon-beta. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZ-01, PEGylated interferon-beta through regulating the expression of Interferon-beta (IFNB1). | [90], [420] | ||
Interferon beta 1a [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Interferon beta 1a. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Interferon beta 1a through regulating the expression of Interferon-beta (IFNB1). | [420], [427] | ||
PF-06823859 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for PF-06823859. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-06823859 through regulating the expression of Interferon-beta (IFNB1). | [420], [427] | ||
ARX-424 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for ARX-424. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ARX-424 through regulating the expression of Interferon-beta (IFNB1). | [420], [428] | ||
Gene therapy, IFN-b [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Gene therapy, IFN-b. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Gene therapy, IFN-b through regulating the expression of Interferon-beta (IFNB1). | [39], [420] | ||
TV-1390 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for TV-1390. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TV-1390 through regulating the expression of Interferon-beta (IFNB1). | [420], [427] | ||
Maxy-10 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Maxy-10. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Maxy-10 through regulating the expression of Interferon-beta (IFNB1). | [420], [429] | ||
Interferon-gamma (IFNG)
Emapalumab [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for Emapalumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Emapalumab through regulating the expression of Interferon-gamma (IFNG). | [65], [430] | ||
| Interferon-gamma (IFNG) is a therapeutic target for Emapalumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Emapalumab through regulating the expression of Interferon-gamma (IFNG). | [65], [369] | |||
Fumaric acid [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for Fumaric acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Fumaric acid through regulating the expression of Interferon-gamma (IFNG). | [65], [431] | ||
VIR-201 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for VIR-201. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VIR-201 through regulating the expression of Interferon-gamma (IFNG). | [65], [432] | ||
AMG 811 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for AMG 811. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMG 811 through regulating the expression of Interferon-gamma (IFNG). | [65], [433] | ||
CIGB-128 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for CIGB-128. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CIGB-128 through regulating the expression of Interferon-gamma (IFNG). | [65], [434] | ||
VPM-4-001 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for VPM-4-001. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VPM-4-001 through regulating the expression of Interferon-gamma (IFNG). | [65], [435] | ||
CRx-191 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for CRx-191. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CRx-191 through regulating the expression of Interferon-gamma (IFNG). | [65], [436] | ||
Fontolizumab [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for Fontolizumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Fontolizumab through regulating the expression of Interferon-gamma (IFNG). | [65], [437] | ||
TAK-603 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for TAK-603. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TAK-603 through regulating the expression of Interferon-gamma (IFNG). | [65], [438] | ||
TG-1042 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for TG-1042. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TG-1042 through regulating the expression of Interferon-gamma (IFNG). | [65], [439] | ||
Interleukin-6 (IL6)
Siltuximab [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for Siltuximab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Siltuximab through regulating the expression of Interleukin-6 (IL6). | [251], [440] | ||
| Interleukin-6 (IL6) is a therapeutic target for Siltuximab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Siltuximab through regulating the expression of Interleukin-6 (IL6). | [251], [442] | |||
Olokizumab [Phase 3]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for Olokizumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Olokizumab through regulating the expression of Interleukin-6 (IL6). | [37], [251] | ||
| Interleukin-6 (IL6) is a therapeutic target for Olokizumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Olokizumab through regulating the expression of Interleukin-6 (IL6). | [251], [441] | |||
Sirukumab [Phase 3]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for Sirukumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sirukumab through regulating the expression of Interleukin-6 (IL6). | [251], [422] | ||
| Interleukin-6 (IL6) is a therapeutic target for Sirukumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sirukumab through regulating the expression of Interleukin-6 (IL6). | [251], [445] | |||
ALD-518 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for ALD-518. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ALD-518 through regulating the expression of Interleukin-6 (IL6). | [37], [251] | ||
CDP-6038 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for CDP-6038. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CDP-6038 through regulating the expression of Interleukin-6 (IL6). | [90], [251] | ||
Clazakizumab [Phase 2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for Clazakizumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Clazakizumab through regulating the expression of Interleukin-6 (IL6). | [37], [251] | ||
| Interleukin-6 (IL6) is a therapeutic target for Clazakizumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Clazakizumab through regulating the expression of Interleukin-6 (IL6). | [251], [443] | |||
PF-04236921 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for PF-04236921. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-04236921 through regulating the expression of Interleukin-6 (IL6). | [251], [444] | ||
YSIL6 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for YSIL6. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of YSIL6 through regulating the expression of Interleukin-6 (IL6). | [90], [251] | ||
C326 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for C326. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of C326 through regulating the expression of Interleukin-6 (IL6). | [251], [446] | ||
Gerilimzumab [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for Gerilimzumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Gerilimzumab through regulating the expression of Interleukin-6 (IL6). | [251], [447] | ||
MEDI5117 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for MEDI5117. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MEDI5117 through regulating the expression of Interleukin-6 (IL6). | [251], [448] | ||
OP-R003 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for OP-R003. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of OP-R003 through regulating the expression of Interleukin-6 (IL6). | [37], [251] | ||
Kruppel like factor 4 (KLF4)
APTO-253 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Kruppel like factor 4 (KLF4) is a therapeutic target for APTO-253. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of APTO-253 through regulating the expression of Kruppel like factor 4 (KLF4). | [99], [449] | ||
Mammalian target of rapamycin complex 1 (mTORC1)
RBT-101 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for RBT-101. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RBT-101 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [450], [451] | ||
AZD-2014 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for AZD-2014. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD-2014 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [450], [452] | ||
ME-344 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for ME-344. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ME-344 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [15], [450] | ||
NV-5138 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for NV-5138. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NV-5138 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [450], [453] | ||
Palomid-529 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for Palomid-529. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Palomid-529 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [15], [450] | ||
VS-5584 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for VS-5584. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VS-5584 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [450], [454] | ||
MAP kinase signal-integrating kinase 2 (MKNK2)
EFT508 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAP kinase signal-integrating kinase 2 (MKNK2) is a therapeutic target for EFT508. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EFT508 through regulating the expression of MAP kinase signal-integrating kinase 2 (MKNK2). | [261], [455] | ||
MAPK/ERK kinase kinase 3 (MAP3K3)
ISIS 122970 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122970. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122970 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [112], [254] | ||
ISIS 122971 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122971. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122971 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [112], [254] | ||
ISIS 122974 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122974. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122974 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [112], [254] | ||
ISIS 122975 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122975. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122975 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [112], [254] | ||
ISIS 122976 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122976. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122976 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [112], [254] | ||
ISIS 122984 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122984. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122984 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [112], [254] | ||
ISIS 122985 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122985. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122985 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [112], [254] | ||
ISIS 122986 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122986. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122986 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [112], [254] | ||
ISIS 122990 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122990. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122990 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [112], [254] | ||
ISIS 122991 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122991. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122991 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [254], [456] | ||
Myb messenger RNA (MYB mRNA)
LR3001 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Myb messenger RNA (MYB mRNA) is a therapeutic target for LR3001. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LR3001 through regulating the expression of Myb messenger RNA (MYB mRNA). | [72], [252] | ||
NAD-dependent deacetylase sirtuin-1 (SIRT1)
GSK2245840 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for GSK2245840. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK2245840 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [458] | ||
MB-12066 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for MB-12066. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MB-12066 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [459] | ||
SEN-196 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SEN-196. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SEN-196 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [460] | ||
SRT2379 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SRT2379. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SRT2379 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [461] | ||
SRT3025 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SRT3025. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SRT3025 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [462] | ||
(R)-sirtinol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for (R)-sirtinol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (R)-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [463] | ||
(S)-sirtinol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for (S)-sirtinol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (S)-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [463] | ||
2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [464] | ||
2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [267], [457] | ||
Meta-sirtinol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for Meta-sirtinol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Meta-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [465] | ||
Para-sirtinol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for Para-sirtinol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Para-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [463] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for RO-316233. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RO-316233 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [464] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for Ro31-8220. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ro31-8220 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [466] | ||
splitomicin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for splitomicin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of splitomicin through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [467] | ||
SRT1720 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SRT1720. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SRT1720 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [463] | ||
YK-3237 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for YK-3237. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of YK-3237 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [466] | ||
GSK184072 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for GSK184072. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK184072 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [457], [468] | ||
NF-kappa-B inhibitor alpha (NFKBIA)
I3C [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NF-kappa-B inhibitor alpha (NFKBIA) is a therapeutic target for I3C. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of I3C through regulating the expression of NF-kappa-B inhibitor alpha (NFKBIA). | [469], [470] | ||
Fucoxanthin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NF-kappa-B inhibitor alpha (NFKBIA) is a therapeutic target for Fucoxanthin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Fucoxanthin through regulating the expression of NF-kappa-B inhibitor alpha (NFKBIA). | [469], [471] | ||
Notch-1 receptor (NOTCH1)
LY3039478 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Notch-1 receptor (NOTCH1) is a therapeutic target for LY3039478. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY3039478 through regulating the expression of Notch-1 receptor (NOTCH1). | [472], [473] | ||
OMP-52M51 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Notch-1 receptor (NOTCH1) is a therapeutic target for OMP-52M51. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of OMP-52M51 through regulating the expression of Notch-1 receptor (NOTCH1). | [15], [472] | ||
Peroxisome proliferator-activated receptor alpha (PPARA)
Bezafibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Bezafibrate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Bezafibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [475] | ||
Ciprofibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Ciprofibrate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ciprofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [476] | ||
Fenofibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Fenofibrate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Fenofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [477] | ||
Lobeglitazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Lobeglitazone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Lobeglitazone through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [478] | ||
Pemafibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Pemafibrate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pemafibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [475] | ||
BMS-298585 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BMS-298585. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS-298585 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [451], [474] | ||
CS-038 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-038. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CS-038 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [479] | ||
GFT-505 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GFT-505. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GFT-505 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [480] | ||
Imiglitazar [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Imiglitazar. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Imiglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [481] | ||
Ragaglitazar [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Ragaglitazar. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ragaglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [482] | ||
TESAGLITAZAR [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TESAGLITAZAR. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TESAGLITAZAR through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [483] | ||
ZYH-1 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZYH-1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ZYH-1 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [484] | ||
GFT14 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GFT14. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GFT14 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [485] | ||
LY-518674 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-518674. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY-518674 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [486] | ||
Naveglitazar [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Naveglitazar. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Naveglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [90], [474] | ||
ONO-5129 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ONO-5129. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ONO-5129 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [487] | ||
ZYH7 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZYH7. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ZYH7 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [488] | ||
AVE0897 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE0897. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AVE0897 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [489] | ||
CDT-fenofibrate [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CDT-fenofibrate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CDT-fenofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [490] | ||
GW-409544 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-409544. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GW-409544 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [491] | ||
Oxeglitazar [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Oxeglitazar. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Oxeglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [492] | ||
TPST-1120 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TPST-1120. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TPST-1120 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [493] | ||
MC-3001 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MC-3001. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MC-3001 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [494] | ||
MC-3002 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MC-3002. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MC-3002 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [495] | ||
PIRINIXIC ACID [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for PIRINIXIC ACID. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PIRINIXIC ACID through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [496] | ||
Romazarit [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Romazarit. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Romazarit through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [90], [474] | ||
(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [497] | ||
(E)-12-Nitrooctadec-12-enoic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-12-Nitrooctadec-12-enoic Acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (E)-12-Nitrooctadec-12-enoic Acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [498] | ||
(E)-13-Nitrooctadec-12-enoic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-13-Nitrooctadec-12-enoic Acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (E)-13-Nitrooctadec-12-enoic Acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [498] | ||
(E)-4-(3,5-dimethoxystyryl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-4-(3,5-dimethoxystyryl)phenol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (E)-4-(3,5-dimethoxystyryl)phenol through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [499] | ||
8S-HETE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for 8S-HETE. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 8S-HETE through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [484] | ||
AD-5061 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AD-5061. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AD-5061 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [500] | ||
BMS-687453 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BMS-687453. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS-687453 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [501] | ||
CP-775146 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CP-775146. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CP-775146 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [394], [474] | ||
DB-900 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DB-900. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DB-900 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [502] | ||
Deoxy-Bigchap [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Deoxy-Bigchap. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Deoxy-Bigchap through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [503] | ||
DRF 2519 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DRF 2519. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DRF 2519 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [504] | ||
eicosatetranoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for eicosatetranoic acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of eicosatetranoic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [505] | ||
Fibrates [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Fibrates. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Fibrates through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [506] | ||
GSK-9578 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GSK-9578. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK-9578 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [498] | ||
GW-2331 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-2331. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GW-2331 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [507] | ||
GW7647 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW7647. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GW7647 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [508] | ||
L-165461 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for L-165461. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of L-165461 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [506] | ||
L-796449 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for L-796449. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of L-796449 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [475] | ||
LL-6531 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LL-6531. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LL-6531 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [509] | ||
LY-465608 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-465608. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY-465608 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [510] | ||
N-oleoylethanolamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for N-oleoylethanolamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N-oleoylethanolamide through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [511] | ||
pristanic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for pristanic acid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of pristanic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [512] | ||
reglitazar [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for reglitazar. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of reglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [513] | ||
TZD18 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TZD18. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TZD18 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [514] | ||
ZY H2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZY H2. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ZY H2 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [515] | ||
Aleglitazar [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Aleglitazar. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Aleglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [516] | ||
AR-H049020 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AR-H049020. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AR-H049020 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [512] | ||
AVE-0847 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE-0847. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AVE-0847 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [517] | ||
AVE-8134 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE-8134. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AVE-8134 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [518] | ||
BM-17.0744 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BM-17.0744. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BM-17.0744 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [90], [474] | ||
BVT-142 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BVT-142. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BVT-142 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [519] | ||
CS-204 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-204. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CS-204 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [520] | ||
CS-207 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-207. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CS-207 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [521] | ||
DRF 10945 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DRF 10945. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DRF 10945 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [522] | ||
E-3030 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for E-3030. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of E-3030 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [523] | ||
GSK-677954 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GSK-677954. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK-677954 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [524] | ||
Indeglitazar [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Indeglitazar. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Indeglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [7], [474] | ||
KRP-101 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-101. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KRP-101 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [525] | ||
KRP-105 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-105. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KRP-105 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [483] | ||
KRP-297 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-297. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KRP-297 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [512] | ||
LG-101280 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LG-101280. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LG-101280 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [526] | ||
LY-929 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-929. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY-929 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [527] | ||
MP-136 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MP-136. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MP-136 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [528] | ||
NS-220 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for NS-220. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NS-220 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [529] | ||
Reglixane [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Reglixane. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Reglixane through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [530] | ||
Sipoglitazar [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Sipoglitazar. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sipoglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [531] | ||
Sodelglitazar [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Sodelglitazar. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sodelglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [474], [532] | ||
PI3-kinase alpha (PIK3CA)
Alpelisib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for Alpelisib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Alpelisib through regulating the expression of PI3-kinase alpha (PIK3CA). | [265], [278] | ||
BAY 80-6946 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for BAY 80-6946. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BAY 80-6946 through regulating the expression of PI3-kinase alpha (PIK3CA). | [265], [533] | ||
Buparlisib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for Buparlisib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Buparlisib through regulating the expression of PI3-kinase alpha (PIK3CA). | [265], [534] | ||
GDC-0032 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for GDC-0032. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GDC-0032 through regulating the expression of PI3-kinase alpha (PIK3CA). | [265], [535] | ||
LY3023414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for LY3023414. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY3023414 through regulating the expression of PI3-kinase alpha (PIK3CA). | [265], [536] | ||
MLN1117 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for MLN1117. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MLN1117 through regulating the expression of PI3-kinase alpha (PIK3CA). | [265], [537] | ||
PA-799 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for PA-799. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PA-799 through regulating the expression of PI3-kinase alpha (PIK3CA). | [265], [538] | ||
BLY719 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for BLY719. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BLY719 through regulating the expression of PI3-kinase alpha (PIK3CA). | [90], [265] | ||
HHCYH33 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for HHCYH33. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HHCYH33 through regulating the expression of PI3-kinase alpha (PIK3CA). | [265], [539] | ||
PWT-33597 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for PWT-33597. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PWT-33597 through regulating the expression of PI3-kinase alpha (PIK3CA). | [265], [540] | ||
ETP-46321 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for ETP-46321. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ETP-46321 through regulating the expression of PI3-kinase alpha (PIK3CA). | [265], [541] | ||
PI3-kinase beta (PIK3CB)
Buparlisib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for Buparlisib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Buparlisib through regulating the expression of PI3-kinase beta (PIK3CB). | [394], [542] | ||
PA-799 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for PA-799. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PA-799 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [543] | ||
PQR309 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for PQR309. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PQR309 through regulating the expression of PI3-kinase beta (PIK3CB). | [535], [542] | ||
AZD8186 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for AZD8186. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD8186 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [544] | ||
BAY 1082439 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for BAY 1082439. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BAY 1082439 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [545] | ||
GSK2636771 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for GSK2636771. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK2636771 through regulating the expression of PI3-kinase beta (PIK3CB). | [90], [542] | ||
3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [546] | ||
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [547] | ||
ISIS 31963 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31963. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 31963 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 31982 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31982. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 31982 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 31996 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31996. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 31996 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32000. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32000 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32002 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32002. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32002 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32003. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32003 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32004 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32004. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32004 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32005 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32005. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32005 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32006 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32006. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32006 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32008 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32008. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32008 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32010 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32010. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32010 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32014 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32014. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32014 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32015 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32015. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32015 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32020 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32020. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32020 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32021 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32021. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32021 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32024 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32024. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32024 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32028 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32028. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32028 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32035 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32035. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32035 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [548] | ||
ISIS 32039 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32039. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 32039 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [549] | ||
KU-0060648 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for KU-0060648. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KU-0060648 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [550] | ||
LY-292223 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for LY-292223. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY-292223 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [549] | ||
PI-3065 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for PI-3065. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PI-3065 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [547] | ||
PIK-75 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for PIK-75. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PIK-75 through regulating the expression of PI3-kinase beta (PIK3CB). | [349], [542] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for PP121. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PP121 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [551] | ||
TGX-221 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for TGX-221. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TGX-221 through regulating the expression of PI3-kinase beta (PIK3CB). | [542], [552] | ||
Protein arginine methyltransferase 1 (PRMT1)
GSK3368715 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 1 (PRMT1) is a therapeutic target for GSK3368715. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK3368715 through regulating the expression of Protein arginine methyltransferase 1 (PRMT1). | [553], [554] | ||
AMI-1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 1 (PRMT1) is a therapeutic target for AMI-1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMI-1 through regulating the expression of Protein arginine methyltransferase 1 (PRMT1). | [553], [555] | ||
RM65 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 1 (PRMT1) is a therapeutic target for RM65. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RM65 through regulating the expression of Protein arginine methyltransferase 1 (PRMT1). | [553], [556] | ||
Protein phosphatase 1A (PPM1A)
VP-102 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein phosphatase 1A (PPM1A) is a therapeutic target for VP-102. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VP-102 through regulating the expression of Protein phosphatase 1A (PPM1A). | [75], [557] | ||
Proto-oncogene c-Myc (MYC)
AVI-5126 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for AVI-5126. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AVI-5126 through regulating the expression of Proto-oncogene c-Myc (MYC). | [368], [558] | ||
Resten-NG [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). | [368], [559] | ||
TWS-119 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). | [42], [368] | ||
RAC-alpha serine/threonine-protein kinase (AKT1)
AZD5363 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for AZD5363. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD5363 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [265] | ||
Enzastaurin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Enzastaurin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Enzastaurin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [560] | ||
GDC-0068 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GDC-0068. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GDC-0068 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [265] | ||
ARQ 092 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 092. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ARQ 092 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [561] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1033. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CI-1033 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [265] | ||
CMX-2043 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CMX-2043. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CMX-2043 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [266] | ||
GSK2110183 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GSK2110183. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GSK2110183 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [562] | ||
PTX-200 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for PTX-200. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PTX-200 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [265] | ||
RX-0201 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RX-0201. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RX-0201 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [563] | ||
Triciribine prodrug [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Triciribine prodrug. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Triciribine prodrug through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [315] | ||
ARQ 751 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 751. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ARQ 751 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [563] | ||
BMS-754807 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS-754807. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS-754807 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [564] | ||
M2698 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for M2698. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of M2698 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [265] | ||
(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [369] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [408] | ||
4,5,6-trihydroxy-3-methylphthalide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6-trihydroxy-3-methylphthalide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4,5,6-trihydroxy-3-methylphthalide through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [369] | ||
A-443654 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-443654. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of A-443654 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [369] | ||
A-674563 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-674563. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of A-674563 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [565] | ||
Akt inhibitor VIII [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Akt inhibitor VIII. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Akt inhibitor VIII through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [394] | ||
ALM-301 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ALM-301. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ALM-301 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [566] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Bisindolylmaleimide-I. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [567] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [369] | ||
BX-517 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BX-517. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BX-517 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [386] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1040. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CI-1040 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [563] | ||
Inositol 1,3,4,5-Tetrakisphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Inositol 1,3,4,5-Tetrakisphosphate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Inositol 1,3,4,5-Tetrakisphosphate through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [568] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for KN-62. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of KN-62 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [567] | ||
Lactoquinomycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Lactoquinomycin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Lactoquinomycin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [569] | ||
LD-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for LD-101. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LD-101 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [563] | ||
MYRIOCIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for MYRIOCIN. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MYRIOCIN through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [570] | ||
NU-1001-41 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for NU-1001-41. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NU-1001-41 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [563] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RO-316233. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RO-316233 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [369] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Ro31-8220. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ro31-8220 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [571] | ||
SB-747651A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for SB-747651A. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SB-747651A through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [376] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for STAUROSPORINONE. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of STAUROSPORINONE through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [570] | ||
VLI-27 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for VLI-27. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VLI-27 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [265], [563] | ||
Squalestatin 1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Squalestatin 1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Squalestatin 1 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [265] | ||
Retinoic acid-inducible gene-1 (RIG-1)
SB-9200 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Retinoic acid-inducible gene-1 (RIG-1) is a therapeutic target for SB-9200. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SB-9200 through regulating the expression of Retinoic acid-inducible gene-1 (RIG-1). | [572], [573] | ||
CV8102 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Retinoic acid-inducible gene-1 (RIG-1) is a therapeutic target for CV8102. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CV8102 through regulating the expression of Retinoic acid-inducible gene-1 (RIG-1). | [572], [574] | ||
MK-4621 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Retinoic acid-inducible gene-1 (RIG-1) is a therapeutic target for MK-4621. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MK-4621 through regulating the expression of Retinoic acid-inducible gene-1 (RIG-1). | [572], [575] | ||
Serine/threonine-protein kinase mTOR (mTOR)
Glasdegib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Glasdegib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Glasdegib through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [577] | ||
Novolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Novolimus. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Novolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [379], [576] | ||
Temsirolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Temsirolimus. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Temsirolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [578] | ||
Zotarolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Zotarolimus. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Zotarolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
Ridaforolimus [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Ridaforolimus. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ridaforolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [579] | ||
ABI-009 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for ABI-009. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABI-009 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [580] | ||
AZD-2014 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AZD-2014. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD-2014 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
BEZ235 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BEZ235. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BEZ235 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [15], [576] | ||
BGT226 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BGT226. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BGT226 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
CC-223 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for CC-223. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CC-223 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [581] | ||
INK128 [Phase 2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for INK128. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of INK128 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [582] | ||
| Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for INK128. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of INK128 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [599] | |||
LY3023414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for LY3023414. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY3023414 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [583] | ||
ME-344 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for ME-344. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ME-344 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [584] | ||
MM-141 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for MM-141. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MM-141 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [15], [576] | ||
OSI-027 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for OSI-027. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of OSI-027 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [585] | ||
PF-04691502 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-04691502. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-04691502 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [586] | ||
PF-05212384 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-05212384. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-05212384 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [537], [576] | ||
PQR309 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PQR309. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PQR309 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [535], [576] | ||
Salirasib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Salirasib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Salirasib through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
SAR245409 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SAR245409. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SAR245409 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [587] | ||
SF1126 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SF1126. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SF1126 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [15], [576] | ||
BI 860585 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BI 860585. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BI 860585 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [588] | ||
DS-3078 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for DS-3078. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DS-3078 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [589] | ||
DS-7423 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for DS-7423. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DS-7423 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [590] | ||
GDC-0349 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for GDC-0349. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GDC-0349 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
LAM-001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for LAM-001. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LAM-001 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [591] | ||
PWT-33597 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PWT-33597. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PWT-33597 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [315], [576] | ||
VS-5584 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for VS-5584. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VS-5584 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [592] | ||
(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [593] | ||
2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [594] | ||
2-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-(6-morpholino-9H-purin-2-yl)phenol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [593] | ||
2-chloro-N-(6-cyanopyridin-3-yl)propanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-chloro-N-(6-cyanopyridin-3-yl)propanamide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-chloro-N-(6-cyanopyridin-3-yl)propanamide through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [595] | ||
2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [596] | ||
3-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 3-(6-morpholino-9H-purin-2-yl)phenol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [593] | ||
4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [593] | ||
4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [597] | ||
4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [593] | ||
4-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(6-morpholino-9H-purin-2-yl)phenol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 4-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [593] | ||
AP-21967 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AP-21967. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AP-21967 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [594] | ||
AR-mTOR-26 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AR-mTOR-26. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AR-mTOR-26 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
C-16-(S)-3-methylindolerapamycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for C-16-(S)-3-methylindolerapamycin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of C-16-(S)-3-methylindolerapamycin through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [593] | ||
CU-906 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for CU-906. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CU-906 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
EC-0565 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EC-0565. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EC-0565 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
EC-0845 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EC-0845. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EC-0845 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
EM-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EM-101. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EM-101 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [598] | ||
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [596] | ||
HM-5016699 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for HM-5016699. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HM-5016699 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
OXA-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for OXA-01. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of OXA-01 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
P-2281 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for P-2281. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of P-2281 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
P-6915 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for P-6915. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of P-6915 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
PF-03772304 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-03772304. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-03772304 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
PF-05094037 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-05094037. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-05094037 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [600] | ||
PP-242 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PP-242. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PP-242 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [340], [576] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PP121. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PP121 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [349], [576] | ||
Rapamycin complexed with immunophilin FKBP12 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Rapamycin complexed with immunophilin FKBP12. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Rapamycin complexed with immunophilin FKBP12 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [596] | ||
SB-2280 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SB-2280. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SB-2280 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
SX-MTR1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SX-MTR1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SX-MTR1 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
torin 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for torin 1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of torin 1 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [349], [576] | ||
Torin2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Torin2. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Torin2 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [601] | ||
X-387 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for X-387. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of X-387 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [263], [576] | ||
AZD8055 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AZD8055. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD8055 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [602] | ||
SCR-44001 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SCR-44001. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SCR-44001 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [603] | ||
TAFA-93 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for TAFA-93. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TAFA-93 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [576], [604] | ||
Signal transducer and activator of transcription 1 (STAT1)
AVT-02 UE [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 1 (STAT1) is a therapeutic target for AVT-02 UE. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AVT-02 UE through regulating the expression of Signal transducer and activator of transcription 1 (STAT1). | [65], [605] | ||
Solute carrier family 40 member 1 (SLC40A1)
LY2928057 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Solute carrier family 40 member 1 (SLC40A1) is a therapeutic target for LY2928057. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY2928057 through regulating the expression of Solute carrier family 40 member 1 (SLC40A1). | [34], [606] | ||
Ferroportin mab [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Solute carrier family 40 member 1 (SLC40A1) is a therapeutic target for Ferroportin mab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ferroportin mab through regulating the expression of Solute carrier family 40 member 1 (SLC40A1). | [34], [607] | ||
M012 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Solute carrier family 40 member 1 (SLC40A1) is a therapeutic target for M012. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of M012 through regulating the expression of Solute carrier family 40 member 1 (SLC40A1). | [34], [608] | ||
SRSF protein kinase 1 (SRPK1)
SPHINX31 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | SRSF protein kinase 1 (SRPK1) is a therapeutic target for SPHINX31. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SPHINX31 through regulating the expression of SRSF protein kinase 1 (SRPK1). | [254], [609] | ||
Target of rapamycin complex 2 MAPKAP1 (MTORC2)
AZD-2014 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Target of rapamycin complex 2 MAPKAP1 (MTORC2) is a therapeutic target for AZD-2014. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AZD-2014 through regulating the expression of Target of rapamycin complex 2 MAPKAP1 (MTORC2). | [394], [610] | ||
ME-344 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Target of rapamycin complex 2 MAPKAP1 (MTORC2) is a therapeutic target for ME-344. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ME-344 through regulating the expression of Target of rapamycin complex 2 MAPKAP1 (MTORC2). | [15], [610] | ||
Palomid-529 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Target of rapamycin complex 2 MAPKAP1 (MTORC2) is a therapeutic target for Palomid-529. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Palomid-529 through regulating the expression of Target of rapamycin complex 2 MAPKAP1 (MTORC2). | [15], [610] | ||
VS-5584 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Target of rapamycin complex 2 MAPKAP1 (MTORC2) is a therapeutic target for VS-5584. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VS-5584 through regulating the expression of Target of rapamycin complex 2 MAPKAP1 (MTORC2). | [453], [610] | ||
Thrombospondin-1 (THBS1)
ABT-510 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thrombospondin-1 (THBS1) is a therapeutic target for ABT-510. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABT-510 through regulating the expression of Thrombospondin-1 (THBS1). | [611], [612] | ||
CVX-045 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thrombospondin-1 (THBS1) is a therapeutic target for CVX-045. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CVX-045 through regulating the expression of Thrombospondin-1 (THBS1). | [611], [613] | ||
Thymidine kinase 1 (TK1)
DEOXYCYTIDINE [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for DEOXYCYTIDINE. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DEOXYCYTIDINE through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
Penciclovir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Penciclovir. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Penciclovir through regulating the expression of Thymidine kinase 1 (TK1). | [368], [614] | ||
TK-DLI [Preregistration]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for TK-DLI. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TK-DLI through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
FV-100 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for FV-100. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of FV-100 through regulating the expression of Thymidine kinase 1 (TK1). | [368], [615] | ||
Radiosensitizer gene therapy [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Radiosensitizer gene therapy. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Radiosensitizer gene therapy through regulating the expression of Thymidine kinase 1 (TK1). | [368], [616] | ||
RP101 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for RP101. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RP101 through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
HQK-1004 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for HQK-1004. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HQK-1004 through regulating the expression of Thymidine kinase 1 (TK1). | [368], [617] | ||
Rilapladib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Rilapladib. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Rilapladib through regulating the expression of Thymidine kinase 1 (TK1). | [368], [618] | ||
Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy through regulating the expression of Thymidine kinase 1 (TK1). | [368], [619] | ||
(South)-Methanocarba-Thymidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for (South)-Methanocarba-Thymidine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of (South)-Methanocarba-Thymidine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [620] | ||
1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [620] | ||
1-[5-(triphenylmethoxy)pentyl]thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 1-[5-(triphenylmethoxy)pentyl]thymine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 1-[5-(triphenylmethoxy)pentyl]thymine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [620] | ||
1-[6-(triphenylmethoxy)hexyl]thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 1-[6-(triphenylmethoxy)hexyl]thymine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 1-[6-(triphenylmethoxy)hexyl]thymine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [620] | ||
1-[7-(triphenylmethoxy)heptyl]thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 1-[7-(triphenylmethoxy)heptyl]thymine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 1-[7-(triphenylmethoxy)heptyl]thymine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [621] | ||
2'-deoxythymidine triphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 2'-deoxythymidine triphosphate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2'-deoxythymidine triphosphate through regulating the expression of Thymidine kinase 1 (TK1). | [368], [618] | ||
2'-Deoxyuridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 2'-Deoxyuridine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2'-Deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [622] | ||
3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [614] | ||
3-(2-propyn-1-yl)thymidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 3-(2-propyn-1-yl)thymidine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-(2-propyn-1-yl)thymidine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [623] | ||
5-Bromothienyldeoxyuridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 5-Bromothienyldeoxyuridine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 5-Bromothienyldeoxyuridine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
5-Iodo-2'-Deoxyuridine-5'-Monophosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 5-Iodo-2'-Deoxyuridine-5'-Monophosphate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 5-Iodo-2'-Deoxyuridine-5'-Monophosphate through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
5-propyl-2'-deoxyuridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 5-propyl-2'-deoxyuridine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 5-propyl-2'-deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [623] | ||
6-(Dihydroxy-Isobutyl)-Thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 6-(Dihydroxy-Isobutyl)-Thymine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6-(Dihydroxy-Isobutyl)-Thymine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
6-Hydroxypropylthymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 6-Hydroxypropylthymine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 6-Hydroxypropylthymine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [624] | ||
9-(4-Hydroxybutyl)-N2-Phenylguanine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 9-(4-Hydroxybutyl)-N2-Phenylguanine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 9-(4-Hydroxybutyl)-N2-Phenylguanine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
9-Hydroxypropyladenine, R-Isomer [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 9-Hydroxypropyladenine, R-Isomer. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 9-Hydroxypropyladenine, R-Isomer through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
9-Hydroxypropyladenine, S-Isomer [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 9-Hydroxypropyladenine, S-Isomer. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 9-Hydroxypropyladenine, S-Isomer through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
BVDU-MP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for BVDU-MP. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BVDU-MP through regulating the expression of Thymidine kinase 1 (TK1). | [368], [625] | ||
Deoxythymidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Deoxythymidine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Deoxythymidine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
Edoxudine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Edoxudine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Edoxudine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [623] | ||
ITdU [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for ITdU. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ITdU through regulating the expression of Thymidine kinase 1 (TK1). | [368], [620] | ||
L-5-(bromovinyl)deoxyuridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for L-5-(bromovinyl)deoxyuridine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of L-5-(bromovinyl)deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [626] | ||
L-5-iodo-2'-deoxyuridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for L-5-iodo-2'-deoxyuridine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of L-5-iodo-2'-deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [623] | ||
N2-(3-trifluoromethylphenyl)guanine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for N2-(3-trifluoromethylphenyl)guanine. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of N2-(3-trifluoromethylphenyl)guanine through regulating the expression of Thymidine kinase 1 (TK1). | [368], [623] | ||
P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
Thymidine-5'-Phosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Thymidine-5'-Phosphate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thymidine-5'-Phosphate through regulating the expression of Thymidine kinase 1 (TK1). | [368], [394] | ||
Sitimagene ceradenovec [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Sitimagene ceradenovec. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Sitimagene ceradenovec through regulating the expression of Thymidine kinase 1 (TK1). | [368], [627] | ||
Tumor necrosis factor (TNF)
Adalimumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Adalimumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Adalimumab through regulating the expression of Tumor necrosis factor (TNF). | [628], [629] | ||
Certolizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Certolizumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Certolizumab through regulating the expression of Tumor necrosis factor (TNF). | [628], [630] | ||
Enbrel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Enbrel. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Enbrel through regulating the expression of Tumor necrosis factor (TNF). | [628], [631] | ||
Etanercept [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Etanercept. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Etanercept through regulating the expression of Tumor necrosis factor (TNF). | [628], [632] | ||
Golimumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Golimumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Golimumab through regulating the expression of Tumor necrosis factor (TNF). | [628], [633] | ||
Infliximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Infliximab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Infliximab through regulating the expression of Tumor necrosis factor (TNF). | [628], [634] | ||
Lenalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Lenalidomide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Lenalidomide through regulating the expression of Tumor necrosis factor (TNF). | [628], [635] | ||
Nafamostat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Nafamostat. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Nafamostat through regulating the expression of Tumor necrosis factor (TNF). | [628], [636] | ||
Pentoxifylline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Pentoxifylline. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pentoxifylline through regulating the expression of Tumor necrosis factor (TNF). | [628], [637] | ||
Thalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Thalidomide. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thalidomide through regulating the expression of Tumor necrosis factor (TNF). | [604], [628] | ||
ABP 501 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABP 501. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABP 501 through regulating the expression of Tumor necrosis factor (TNF). | [628], [638] | ||
CPL-7075 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CPL-7075. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CPL-7075 through regulating the expression of Tumor necrosis factor (TNF). | [628], [639] | ||
Golnerminogene pradenovac [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Golnerminogene pradenovac. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Golnerminogene pradenovac through regulating the expression of Tumor necrosis factor (TNF). | [628], [640] | ||
PF-06410293 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-06410293. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-06410293 through regulating the expression of Tumor necrosis factor (TNF). | [628], [641] | ||
PF-06438179 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-06438179. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-06438179 through regulating the expression of Tumor necrosis factor (TNF). | [628], [642] | ||
ABT-122 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABT-122. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABT-122 through regulating the expression of Tumor necrosis factor (TNF). | [628], [643] | ||
AN0128 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AN0128. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AN0128 through regulating the expression of Tumor necrosis factor (TNF). | [628], [644] | ||
AP-301-IH [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AP-301-IH. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AP-301-IH through regulating the expression of Tumor necrosis factor (TNF). | [628], [645] | ||
ART621 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ART621. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ART621 through regulating the expression of Tumor necrosis factor (TNF). | [313], [628] | ||
BAICALEIN [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for BAICALEIN. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BAICALEIN through regulating the expression of Tumor necrosis factor (TNF). | [628], [646] | ||
COVA322 [Phase 1/2a]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for COVA322. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of COVA322 through regulating the expression of Tumor necrosis factor (TNF). | [628], [647] | ||
DLX-105 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for DLX-105. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DLX-105 through regulating the expression of Tumor necrosis factor (TNF). | [628], [648] | ||
ESBA-105 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ESBA-105. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ESBA-105 through regulating the expression of Tumor necrosis factor (TNF). | [628], [649] | ||
Ortataxel [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Ortataxel. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ortataxel through regulating the expression of Tumor necrosis factor (TNF). | [628], [650] | ||
Pegsunercept [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Pegsunercept. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Pegsunercept through regulating the expression of Tumor necrosis factor (TNF). | [628], [651] | ||
RDP58 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for RDP58. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RDP58 through regulating the expression of Tumor necrosis factor (TNF). | [628], [652] | ||
TNF alpha kinoid [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for TNF alpha kinoid. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TNF alpha kinoid through regulating the expression of Tumor necrosis factor (TNF). | [628], [653] | ||
ABBV-257 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABBV-257. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABBV-257 through regulating the expression of Tumor necrosis factor (TNF). | [628], [654] | ||
AST-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AST-005. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AST-005 through regulating the expression of Tumor necrosis factor (TNF). | [37], [628] | ||
AVX-470 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AVX-470. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AVX-470 through regulating the expression of Tumor necrosis factor (TNF). | [37], [628] | ||
CYT-609 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CYT-609. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CYT-609 through regulating the expression of Tumor necrosis factor (TNF). | [628], [655] | ||
INB03 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for INB03. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of INB03 through regulating the expression of Tumor necrosis factor (TNF). | [628], [656] | ||
PF-05230905 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-05230905. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-05230905 through regulating the expression of Tumor necrosis factor (TNF). | [39], [628] | ||
PMI-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PMI-005. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PMI-005 through regulating the expression of Tumor necrosis factor (TNF). | [628], [657] | ||
ABX-0401 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABX-0401. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABX-0401 through regulating the expression of Tumor necrosis factor (TNF). | [6], [628] | ||
Celastrol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Celastrol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Celastrol through regulating the expression of Tumor necrosis factor (TNF). | [90], [628] | ||
2-Propanol, Isopropanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for 2-Propanol, Isopropanol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Tumor necrosis factor (TNF). | [628], [658] | ||
DOM-0215 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for DOM-0215. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DOM-0215 through regulating the expression of Tumor necrosis factor (TNF). | [628], [659] | ||
IK-862 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for IK-862. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of IK-862 through regulating the expression of Tumor necrosis factor (TNF). | [628], [660] | ||
PKF-241-466 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PKF-241-466. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PKF-241-466 through regulating the expression of Tumor necrosis factor (TNF). | [628], [660] | ||
PKF-242-484 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PKF-242-484. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PKF-242-484 through regulating the expression of Tumor necrosis factor (TNF). | [507], [628] | ||
Y-39041 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Y-39041. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Y-39041 through regulating the expression of Tumor necrosis factor (TNF). | [628], [661] | ||
ALS-00T2-0501 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ALS-00T2-0501. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ALS-00T2-0501 through regulating the expression of Tumor necrosis factor (TNF). | [628], [662] | ||
AME-527 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AME-527. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AME-527 through regulating the expression of Tumor necrosis factor (TNF). | [628], [659] | ||
Camobucol [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Camobucol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Camobucol through regulating the expression of Tumor necrosis factor (TNF). | [628], [663] | ||
CDP571 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CDP571. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CDP571 through regulating the expression of Tumor necrosis factor (TNF). | [628], [664] | ||
CRx-191 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CRx-191. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CRx-191 through regulating the expression of Tumor necrosis factor (TNF). | [628], [665] | ||
CYT-007-TNFQb [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CYT-007-TNFQb. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CYT-007-TNFQb through regulating the expression of Tumor necrosis factor (TNF). | [435], [628] | ||
FR-133605 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for FR-133605. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of FR-133605 through regulating the expression of Tumor necrosis factor (TNF). | [628], [666] | ||
ISIS 104838 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ISIS 104838. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 104838 through regulating the expression of Tumor necrosis factor (TNF). | [628], [667] | ||
MDL-201112 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for MDL-201112. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MDL-201112 through regulating the expression of Tumor necrosis factor (TNF). | [628], [668] | ||
PNU-282987 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PNU-282987. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PNU-282987 through regulating the expression of Tumor necrosis factor (TNF). | [26], [628] | ||
Segard [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Segard. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Segard through regulating the expression of Tumor necrosis factor (TNF). | [628], [669] | ||
TNFQb therapeutic vaccines [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for TNFQb therapeutic vaccines. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TNFQb therapeutic vaccines through regulating the expression of Tumor necrosis factor (TNF). | [628], [670] | ||
Tyrosine-protein kinase EIF2AK2 (p68)
ASN-11124542 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase EIF2AK2 (p68) is a therapeutic target for ASN-11124542. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ASN-11124542 through regulating the expression of Tyrosine-protein kinase EIF2AK2 (p68). | [671], [672] | ||
NU6140 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase EIF2AK2 (p68) is a therapeutic target for NU6140. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NU6140 through regulating the expression of Tyrosine-protein kinase EIF2AK2 (p68). | [671], [673] | ||
Ubiquitin-protein ligase E3 Mdm2 (MDM2)
RG7388 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for RG7388. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RG7388 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [674] | ||
ALRN-6924 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ALRN-6924. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ALRN-6924 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [675] | ||
AMG 232 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for AMG 232. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMG 232 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [15], [89] | ||
APG-115 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for APG-115. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of APG-115 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [676] | ||
ASTX295 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ASTX295. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ASTX295 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [677] | ||
BI 907828 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for BI 907828. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BI 907828 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [678] | ||
DS-3032 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for DS-3032. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of DS-3032 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [679] | ||
HDM201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for HDM201. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of HDM201 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [680] | ||
JNJ-26854165 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for JNJ-26854165. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of JNJ-26854165 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [15], [89] | ||
RG7775 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for RG7775. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RG7775 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [681] | ||
ISIS 16507 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ISIS 16507. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 16507 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [74], [89] | ||
ISIS 16518 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ISIS 16518. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 16518 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [104] | ||
MI-219 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for MI-219. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MI-219 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [682] | ||
NSC-66811 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for NSC-66811. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NSC-66811 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [683] | ||
NU-8231 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for NU-8231. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NU-8231 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [684] | ||
NUTLIN-3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for NUTLIN-3. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of NUTLIN-3 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [685] | ||
PLSQETFSDLWKLLPEN-NH2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for PLSQETFSDLWKLLPEN-NH2. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PLSQETFSDLWKLLPEN-NH2 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [89], [686] | ||
Vacuolar-type proton ATPase catalytic A (v-ATPase-A)
Cruentaren [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vacuolar-type proton ATPase catalytic A (v-ATPase-A) is a therapeutic target for Cruentaren. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cruentaren through regulating the expression of Vacuolar-type proton ATPase catalytic A (v-ATPase-A). | [254], [687] | ||
References